Perifollicular Fibrosis in AGA: Why the Collagen Axis...

The Hormone-Centric Narrative and What It Misses

For decades, the standard narrative around androgenetic alopecia has centered on androgens and the hair follicle cycle: dihydrotestosterone binds androgen receptors in dermal papilla cells, triggers premature catagen entry, and progressively miniaturizes terminal follicles into vellus-like structures. This model is correct as far as it goes. The problem is that it does not go far enough.

A growing body of histological evidence shows that the tissue surrounding miniaturizing follicles undergoes significant structural remodeling — and that this remodeling may not be a passive consequence of miniaturization but an active contributor to its persistence. The perifollicular collagen axis, long treated as a footnote in AGA research, is returning to the center of the discussion.

Understanding this axis matters for product development because it opens a distinct mechanistic lane — one that ingredients like DPO (diaminopyrimidine oxide, aminexil) are positioned to address. But understanding it also requires confronting the limitations of current evidence and the terminology errors that have accumulated around DPO's mechanism over three decades of commercialization.

What the Histology Literature Actually Shows

Classic Observations

The histological case for perifollicular fibrosis in AGA rests on several foundational studies. Jaworsky, Kligman, and Murphy (1992, British Journal of Dermatology) characterized inflammatory infiltrates in male pattern alopecia, documenting perifollicular lymphocytic inflammation and collagenous streamers around miniaturizing follicles. Their work established that inflammation and fibrotic change are not incidental findings in AGA scalps but consistent features associated with progressive hair loss.

Whiting (1993, Journal of the American Academy of Dermatology) introduced horizontal sectioning of scalp biopsies as a diagnostic methodology and described perifollicular collagenous thickening as a recurring observation in AGA specimens. While Whiting's work focused primarily on the diagnostic value of follicular miniaturization ratios, the fibrotic changes he documented have been cited repeatedly as evidence for matrix remodeling in AGA.

Contemporary Reinforcement

More recent work has strengthened rather than weakened this thread. Umar, Tan, and Shitabata (2026, Clinical, Cosmetic and Investigational Dermatology) provide contemporary evidence for perifollicular fibrosis and inflammation as factors in AGA progression, supporting the view that collagen remodeling is not merely historical observation but an active area of investigation with therapeutic implications.

Li et al. (2025, Skin Appendage Disorders) published a review framing perifollicular fibrosis explicitly as a modifiable axis in AGA, with collagen cross-linking pathways identified as potential intervention targets. This represents a meaningful shift from the older literature, which tended to describe fibrosis observationally rather than therapeutically.

Liu et al. (2025, Nature Reviews Disease Primers) position AGA as a multifactorial condition involving androgen signaling, genetic susceptibility, Wnt pathway modulation, and inflammatory-fibrotic remodeling interactions. The inclusion of fibrotic remodeling as a named axis in a major primer-level review signals that the field has moved beyond treating it as peripheral.

The Causality Question

The central unresolved question is directionality: does perifollicular fibrosis contribute to miniaturization, or does miniaturization produce fibrosis as a secondary consequence? The honest answer is that the evidence supports both possibilities, and they are not mutually exclusive.

The emerging consensus, as framed in contemporary reviews, favors a feedback model: microinflammation triggers TGF-β and Smad-driven myofibroblast activation, which drives collagen deposition and matrix stiffening, which in turn disrupts dermal papilla signaling and impairs follicular cycling. In this model, fibrosis is both consequence and contributor — a vicious cycle rather than a one-directional cause.

For product development purposes, the practical implication is clear: whether fibrosis is primary or secondary, reducing perifollicular collagen rigidification is a rational strategy with histological support. The question is whether any available cosmetic ingredient can meaningfully do so.

DPO's Mechanism: What the Published Record Actually Supports

The Mahé 1996 Paper

The foundational mechanistic study for DPO is Mahé, Buan, and Bernard (1996, Skin Pharmacology). Using RT-PCR in a structure-activity framework, they demonstrated that 2,4-diaminopyrimidine-3-oxide (aminexil) — the compound lacking the C6 piperidinyl group present in minoxidil — retains strong inhibition of lysyl hydroxylase mRNA expression in vitro.

The significance of this finding is that it identified a mechanism for DPO that is independent of K_ATP channel biology. DPO was specifically selected from over 150 pyrimidine N-oxide derivatives because it retained anti-lysyl hydroxylase activity without the vasodilatory and antihypertensive effects associated with minoxidil's channel-opening activity. L'Oréal's original patent (US 4,973,474, filed 1989) covers 2,4-diaminopyrimidine-3-oxide derivatives for hair loss treatment and prevention on this basis.

The Murad and Pinnell Foundation

The broader context comes from Murad and Pinnell (1987, Journal of Biological Chemistry), who established that minoxidil suppresses lysyl hydroxylase activity in cultured fibroblasts at concentrations of 25–500 µM. Recovery was blocked by actinomycin D, confirming that the mechanism operates at the transcriptional level — this is mRNA suppression, not direct enzyme inhibition. No Ki or IC₅₀ values have been published for DPO against lysyl hydroxylase protein.

Murad et al. (1992, Archives of Biochemistry and Biophysics) extended the SAR analysis, demonstrating that the C6 substituent structure affects which biological activities are retained. The pyrrolidine substitution in PDPO abolished lysyl hydroxylase inhibitory activity, while DPO — lacking any C6 substituent entirely — retained it. This SAR data is important because it shows that the lysyl hydroxylase mechanism is pharmacophore-dependent but separable from the potassium channel mechanism.

The Enzyme Identity Error

This is where the terminology problem becomes critical. Lysyl hydroxylase (encoded by PLOD genes) is an Fe²⁺/2-oxoglutarate-dependent dioxygenase that hydroxylates lysine residues in procollagen, a modification required for subsequent stable cross-link formation. Lysyl oxidase (LOX) is a copper-dependent amine oxidase that catalyzes a different reaction — oxidative deamination of lysine and hydroxylysine residues in collagen and elastin to form allysine, enabling covalent cross-linking of mature fibers.

These are fundamentally different enzymes. They have different substrates, different cofactors (iron versus copper), different genomic locations, and different positions in the collagen maturation cascade. Lysyl hydroxylase acts on procollagen intracellularly; lysyl oxidase acts on secreted collagen extracellularly.

The published peer-reviewed evidence for DPO supports modulation of lysyl hydroxylase mRNA expression. The widespread description of DPO as a "lysyl oxidase inhibitor" in marketing materials, product pages, and even some corporate press materials does not reflect the primary literature. This conflation has persisted for over two decades, and it undermines the scientific credibility of DPO-based claims with the technical audience — dermatologists, formulation scientists, and regulatory reviewers — that matters most for serious product positioning.

The SCCNFP (2000) concluded that DPO is "not a derivative of Minoxidil" and that its pharmacological activity is "unknown" — language that reflected the committee's assessment that the mechanism had not been fully characterized by pharmaceutical standards, even if L'Oréal's in-house research had identified the lysyl hydroxylase thread.

TGF-β, Oxidative Stress, and the Broader Fibrosis Cascade

Androgen-Inducible TGF-β1

Perifollicular fibrosis in AGA does not occur in isolation. It connects to the androgen-signaling axis through TGF-β1. Inui et al. (2003, Journal of Investigative Dermatology Symposium Proceedings) identified androgen-inducible TGF-β1 from dermal papilla cells as a key mediator suppressing epithelial growth in AGA. TGF-β1 is both a catagen-promoting signal and a potent pro-fibrotic factor — it drives Smad-dependent transcription of collagen genes, activates myofibroblasts, and promotes extracellular matrix deposition.

Shin et al. (2013, BMB Reports) demonstrated that the induction of TGF-β1 by androgens in dermal papilla cells is mediated by reactive oxygen species. This ROS-TGF-β1 link is significant because it connects oxidative stress — a potentially modifiable factor — to the fibrotic cascade. NAC, an antioxidant and cysteine donor mechanistically similar to OTZ, was shown to suppress androgen-inducible TGF-β1 in dermal papilla cells in the same body of work.

TGF-β2 in Catagen

It is worth noting that TGF-β2, not TGF-β1, appears to be the primary isoform driving catagen induction in human hair follicles (Hibino and Nishiyama, 2004, Journal of Dermatological Science). TGF-β1 knockout mice show delayed catagen (Foitzik et al., 2000, FASEB Journal), confirming the isoform's involvement in follicle regression, but the relative contributions of β1 and β2 in human AGA remain an area of active investigation.

How This Connects to DPO

The relevance of TGF-β biology to DPO is indirect but meaningful. TGF-β drives fibrosis through the same collagen deposition and maturation cascade that lysyl hydroxylase participates in. If DPO reduces lysyl hydroxylase expression — as the Mahé data supports — it addresses a downstream component of the TGF-β-driven fibrotic program. This creates a rational basis for combination strategies pairing anti-fibrotic (DPO) with antioxidant/GSH-supporting (OTZ) approaches, since they target different points in the same pathological cascade.

However, this complementarity is conceptual. No published study has directly tested whether DPO and OTZ produce additive or synergistic effects on perifollicular collagen remodeling or any follicular endpoint.

Clinical Evidence: Supportive but Not Definitive

What Exists

The clinical evidence for DPO is concentrated in product-level studies of multi-ingredient formulations:

• Reygagne et al. (2021, Dermatologic Therapy): An observational study of 527 subjects using Aminexil Clinical 5, a multi-ingredient product. Pull test reduction of 82% in men at day 90 (p < 0.01). Open-label, no placebo control, multiple L'Oréal-affiliated authors.
• Piraccini et al. (2011, Giornale Italiano di Dermatologia e Venereologia): Open-label study of aminexil plus arginine. Pull test reduction of 67.7% at 45 days, 82% at 90 days in men. No placebo, multi-ingredient.
• Jalilzadeh et al. (2024, BioImpacts): Controlled mouse model comparing 5% kopexil versus 5% minoxidil over 28 days. Kopexil showed significantly higher hair weight, follicle count, anagen percentage, and VEGF/HGF expression. Preclinical only.

What Does Not Exist

No published, independent, placebo-controlled, DPO-monotherapy human trial with phototrichogram or trichoscopy endpoints has been identified in the peer-reviewed literature. No study has demonstrated histological reversal of perifollicular fibrosis by DPO in human scalp biopsies. These are the evidence gaps that separate DPO's mechanistic rationale from pharmaceutical-grade clinical proof.

A Vichy-sponsored RCT (NCT06590779) has been registered but results have not yet been published.

Evidence Limits Worth Stating Clearly

• Human scalp histology showing DPO-mediated reduction in perifollicular fibrosis has not been published.
• Lysyl oxidase enzyme kinetics (Ki/IC₅₀) for DPO have not been reported in peer-reviewed literature.
• Clinical outcomes are from multi-ingredient, sponsor-funded, open-label studies.
• DPO likely lacks K_ATP channel opening activity based on SAR data (Murad 1992), so combining it with DPO's "anti-fibrotic" positioning and K_ATP-related claims in the same product narrative is problematic unless two distinct active ingredients are being referenced.
• Competitive benchmarking against minoxidil — which has extensive, independent, controlled clinical evidence — should be framed carefully.

Implications for R&D Programs

For teams building scalp products around the fibrosis axis, this evidence landscape changes study design in three important ways.

First, endpoint selection matters. Pull tests and subjective assessments are insufficient to substantiate an anti-fibrotic mechanism. Programs that take this pathway seriously need longer follow-up periods and structure-sensitive endpoints — trichoscopy-derived measures, possibly scalp biopsies with collagen staining in early-phase work.

Second, attribution discipline matters. If the product is a multi-ingredient formula, the study should be designed to test the formula, not make claims about individual ingredients that the design cannot support. Alternatively, monotherapy arms can be included specifically to address attribution.

Third, terminology accuracy matters. Describing DPO as a "lysyl oxidase inhibitor" when the published evidence supports lysyl hydroxylase transcriptional modulation is not merely imprecise — it is the kind of error that sophisticated buyers, dermatologists, and regulatory reviewers will notice and penalize. The collagen maturation modulation narrative is strong enough on its own merits; it does not need to borrow from a different enzyme.

Competitive Context: Why Fibrosis Is an Under-Addressed Lane

Most competing cosmetic hair actives — Redensyl, Capixyl, Procapil, caffeine, saw palmetto extracts — position around follicle stimulation, DHT reduction, or general antioxidant support. Very few address the perifollicular tissue environment directly. This creates a meaningful differentiation opportunity for products that can credibly claim anti-fibrotic or collagen-maturation-modulating activity.

DPO's published evidence, while not pharmaceutical-grade, is specifically relevant to this lane. The Mahé 1996 data — lysyl hydroxylase mRNA suppression in a structure-activity framework — is mechanistically precise enough to survive scrutiny from technical buyers and regulatory reviewers, provided it is communicated accurately (lysyl hydroxylase, not lysyl oxidase; transcriptional modulation, not enzyme kinetics; in vitro, not clinical histological reversal).

The broader opportunity is real. Perifollicular fibrosis represents a distinct pathological axis in AGA that is not well addressed by existing cosmetic actives. Products that can credibly position around this mechanism — with accurate science, transparent evidence hierarchy, and commitment to closing the data gaps — will have a structural advantage in a market increasingly demanding scientific rigor.